Orelabrutinib in the Treatment of Relapsed/Refractory AIHA | MicrobiomeTrials← Back to trialsNCT07453368
Orelabrutinib in the Treatment of Relapsed/Refractory AIHA
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-03-01Est. Completion: 2027-03-01
Enrollment target: 50 participants Locations- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Systemic Lupus ErythematosusAutoimmune Hemolytic Anemia (AIHA)
This is an open lable and single arm study designed to evaluate the safety, PK and PD of Arnovie101 in B cell-mediated A…
Beijing, ChinaEst. completion May 30, 2027
B-cell Acute Lymphoblastic Leukemia (B-ALL)Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (B-NHL)Autoimmune Hemolytic Anemia (AIHA)
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapse…
Zhengzhou, ChinaEst. completion Nov 30, 2027